0001104659-21-145951.txt : 20211202 0001104659-21-145951.hdr.sgml : 20211202 20211202170027 ACCESSION NUMBER: 0001104659-21-145951 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20211130 FILED AS OF DATE: 20211202 DATE AS OF CHANGE: 20211202 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Yang Arvin CENTRAL INDEX KEY: 0001834321 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38129 FILM NUMBER: 211467542 MAIL ADDRESS: STREET 1: 840 MEMORIAL DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Mersana Therapeutics, Inc. CENTRAL INDEX KEY: 0001442836 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 840 MEMORIAL DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-498-0020 MAIL ADDRESS: STREET 1: 840 MEMORIAL DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: MERSANA THERAPEUTICS INC DATE OF NAME CHANGE: 20080813 4 1 tm2134477-1_4seq1.xml OWNERSHIP DOCUMENT X0306 4 2021-11-30 0 0001442836 Mersana Therapeutics, Inc. MRSN 0001834321 Yang Arvin C/O MERSANA THERAPEUTICS, INC. 840 MEMORIAL DRIVE CAMBRIDGE MA 02139 0 1 0 0 Chief Medical Officer Common Stock 2021-11-30 4 M 0 18500 A 18500 D Common Stock 2021-12-01 4 S 0 5527 6.81 D 12973 D Restricted Stock Units 2021-11-30 4 M 0 18500 0 D Common Stock 18500 18500 D Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock upon settlement. Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs listed in Table II. These sales were mandated by the Issuer's election under its equity incentive plans to require the reporting person to sell a number of shares of common stock needed to satisfy his tax withholding obligations and does not represent a discretionary trade by the reporting person. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $6.68 to $7.00, inclusive. The reporting person undertakes to provide to Mersana Therapeutics, Inc., any security holder of Mersana Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4. 50% of the total number of RSUs vested on November 30, 2021, and the remainder of the total number of RSUs shall vest on November 30, 2022. Brian DeSchuytner, as Attorney-in-Fact 2021-12-02